胰腺临床试验入组的障碍。

Shubham Pant, Michael S Lee
{"title":"胰腺临床试验入组的障碍。","authors":"Shubham Pant,&nbsp;Michael S Lee","doi":"10.46883/ONC.2020.3410.0407.1","DOIUrl":null,"url":null,"abstract":"<p><p>Pancreatic cancer is the third leading cause of cancer mortality in the United States, causing an estimated 47,050 deaths in the year 2020, and had the lowest 5-year relative survival of any cancer type diagnosed in 2009-2015, at only 9%. In light of this limited prognosis, consensus guidelines from ASCO and NCCN recommend that patients be informed about and/or managed in clinical trials. However, only 4.16% of patients with pancreatic cancer ultimately enrolled in clinical trials in 2014, while enrollment to existing trials is noted to be unacceptably slow.</p>","PeriodicalId":520728,"journal":{"name":"Oncology (Williston Park, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Barriers to Pancreatic Clinical Trials Enrollment.\",\"authors\":\"Shubham Pant,&nbsp;Michael S Lee\",\"doi\":\"10.46883/ONC.2020.3410.0407.1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Pancreatic cancer is the third leading cause of cancer mortality in the United States, causing an estimated 47,050 deaths in the year 2020, and had the lowest 5-year relative survival of any cancer type diagnosed in 2009-2015, at only 9%. In light of this limited prognosis, consensus guidelines from ASCO and NCCN recommend that patients be informed about and/or managed in clinical trials. However, only 4.16% of patients with pancreatic cancer ultimately enrolled in clinical trials in 2014, while enrollment to existing trials is noted to be unacceptably slow.</p>\",\"PeriodicalId\":520728,\"journal\":{\"name\":\"Oncology (Williston Park, N.Y.)\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology (Williston Park, N.Y.)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.46883/ONC.2020.3410.0407.1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology (Williston Park, N.Y.)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.46883/ONC.2020.3410.0407.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

胰腺癌是美国癌症死亡的第三大原因,在2020年估计造成47,050人死亡,并且在2009-2015年诊断的所有癌症类型中,胰腺癌的5年相对生存率最低,仅为9%。鉴于这种有限的预后,ASCO和NCCN的共识指南建议告知患者和/或在临床试验中进行管理。然而,2014年只有4.16%的胰腺癌患者最终参加了临床试验,而现有试验的入组速度慢得令人无法接受。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Barriers to Pancreatic Clinical Trials Enrollment.

Pancreatic cancer is the third leading cause of cancer mortality in the United States, causing an estimated 47,050 deaths in the year 2020, and had the lowest 5-year relative survival of any cancer type diagnosed in 2009-2015, at only 9%. In light of this limited prognosis, consensus guidelines from ASCO and NCCN recommend that patients be informed about and/or managed in clinical trials. However, only 4.16% of patients with pancreatic cancer ultimately enrolled in clinical trials in 2014, while enrollment to existing trials is noted to be unacceptably slow.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信